There is no single test that definitively confirms either multiple sclerosis (MS) or Parkinson’s disease. Both are diagnosed through a combination of clinical exams, imaging, and lab work, with doctors piecing together evidence while ruling out other conditions that mimic the symptoms. The process differs significantly for each disease, so understanding what to expect for each one can help you prepare.
How MS Is Diagnosed
MS diagnosis follows a framework called the McDonald criteria, which requires doctors to show that damage has occurred in at least two separate areas of the central nervous system at two different points in time. This concept, known as “dissemination in space and time,” is the cornerstone of an MS diagnosis. The criteria also require that no other condition better explains the symptoms.
Most people start the diagnostic process after a first episode of neurological symptoms, such as vision problems, numbness, or difficulty walking. From there, doctors use a combination of MRI scans, spinal fluid analysis, and nerve conduction tests to build the case.
MRI Scans
MRI is the most important tool in MS diagnosis. It reveals the characteristic lesions, or areas of damage, scattered across the brain and spinal cord. These lesions appear in both white matter and gray matter, including areas like the basal ganglia, thalamus, and brainstem. Some lesions light up with contrast dye, indicating active inflammation, while older lesions do not. Finding both active and inactive lesions on a single scan can satisfy the requirement for damage at different points in time, sometimes allowing a diagnosis from one MRI session.
Spinal Fluid Analysis
A lumbar puncture (spinal tap) checks for specific immune markers in the fluid surrounding your brain and spinal cord. The key finding is oligoclonal bands, which are distinct patterns of immune proteins not found in the blood. These bands appear in about 93% of people with MS. In a large study from an Austrian medical center analyzing over 5,000 patients, oligoclonal bands had a sensitivity of 92.8% and specificity of 90.4% for MS. Perhaps most useful: if the test comes back negative, there’s a 98.7% chance you don’t have MS, making it an excellent tool for ruling the disease out.
Evoked Potential Tests
Visual evoked potential (VEP) testing measures how quickly electrical signals travel from your eyes to your brain. You watch a shifting checkerboard pattern on a screen while electrodes on your scalp record the response. In MS, the protective coating on nerve fibers is damaged, slowing signal transmission. VEP testing picks up on this delay by measuring the latency of a specific brainwave called the P100 wave. This test can sometimes detect nerve damage that doesn’t show up on MRI, particularly along the optic nerve. The biggest delays tend to appear in people who have had MS for a long time or have a progressive form of the disease.
Blood Work for Ruling Out Other Conditions
No blood test confirms MS, but blood work is essential for eliminating conditions that look similar. Your doctor will likely check vitamin B12 and folate levels, since B12 deficiency causes spinal cord damage that closely mimics MS on imaging. Thyroid function, HIV and hepatitis serology, and markers for lupus and other autoimmune diseases are also standard. If your symptoms involve mainly the optic nerves or spinal cord, testing for anti-aquaporin-4 antibodies helps distinguish neuromyelitis optica spectrum disorder (NMOSD) from MS. These antibodies are highly specific for NMOSD, though they can be negative in 30 to 40% of cases, so anti-MOG antibodies may also be checked.
How Parkinson’s Disease Is Diagnosed
Parkinson’s diagnosis is primarily clinical, meaning it relies heavily on a neurologist’s examination rather than a scan or lab test. The core requirement is bradykinesia, a noticeable slowness of movement, combined with either a resting tremor or muscle rigidity. Without bradykinesia, a Parkinson’s diagnosis cannot be made regardless of other symptoms.
From there, the neurologist looks for supportive features that increase diagnostic confidence and checks for red flags that might point to a different condition. Supportive features include a tremor that occurs at rest, a clear response to dopamine-boosting medication, and a loss of smell. Red flags include early severe balance problems, rapid progression, or a lack of any response to medication.
The Levodopa Challenge
One of the most practical diagnostic steps is a trial of levodopa, the medication that replaces the brain chemical dopamine. If your motor symptoms improve by roughly 33% or more, that counts as a positive response and supports the diagnosis. Research from the DeNoPa cohort found that using this 33% threshold gives about 70% sensitivity and 71% specificity. A strong response doesn’t guarantee Parkinson’s, and a weak response doesn’t rule it out entirely, but it’s a meaningful data point in the overall picture.
DaTscan Imaging
When the diagnosis is uncertain, particularly when it’s hard to tell Parkinson’s apart from essential tremor or other movement disorders, a DaTscan can help. This specialized brain scan uses a small amount of radioactive tracer to visualize the dopamine-producing nerve terminals in the brain. In Parkinson’s, these terminals are depleted, creating a visibly abnormal scan pattern. A systematic review found that DaTscan achieves 98% sensitivity and 98% specificity in patients with clinically uncertain parkinsonism, making it highly reliable in that specific scenario.
Standard MRI, by contrast, typically appears normal in early Parkinson’s disease. MRI is useful mainly for ruling out other causes of movement problems, like strokes or brain tumors, rather than confirming Parkinson’s itself.
Skin Biopsy for Alpha-Synuclein
A newer diagnostic option involves a small skin biopsy, usually taken from the back of the neck or leg. The test looks for abnormal clumps of a protein called phosphorylated alpha-synuclein in the nerve fibers of the skin. According to NIH-funded research, this protein was detected in 93% of people with clinically confirmed Parkinson’s and in only 3% of healthy controls. This test is becoming more widely available and offers a relatively simple way to confirm the presence of the underlying disease process. A related approach, the seed amplification assay performed on spinal fluid, can detect the same abnormal protein with high accuracy and may even help predict how quickly the disease will progress.
Key Differences in the Diagnostic Process
The two conditions are rarely confused with each other, since their symptoms are quite different. MS typically involves episodes of neurological problems (vision loss, numbness, weakness) that come and go, while Parkinson’s presents as a gradually worsening movement disorder. But the diagnostic journeys share one important similarity: both take time, and neither has a single yes-or-no test.
For MS, expect the process to center on MRI and possibly a lumbar puncture, with extensive blood work to rule out mimics. The timeline can range from weeks to months, depending on whether the MRI findings are clear-cut or require follow-up scans to demonstrate new activity. For Parkinson’s, the process is often faster in straightforward cases, relying on a neurologist’s clinical assessment and a medication trial. DaTscan or skin biopsy may be added when symptoms are atypical or the diagnosis is in question.
In both cases, the neurologist is looking not just for evidence that fits the diagnosis, but for anything that doesn’t fit. A diagnosis of MS or Parkinson’s is only valid when no other condition better explains the full picture.